Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.39 |
| ▸ | DRD3 | P35462 | 4/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | CD44 | P16070 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | KDM1A | O60341 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7797306 | 0.81 | MEN1 (0.36) | CD44KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL22587954 | 0.77 | MTNR1A (0.33) | CD44KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL31285945 | 0.77 | MTNR1A (0.33) | CD44KDM4EMEN1ALDH1A1LMNA | |
| SCHEMBL7372246 | 0.74 | HTR1A (0.37) | HTR1A | |
| SCHEMBL7351217 | 0.73 | FYN (0.38) | HTR1ASIGMAR1 | |
| SCHEMBL21447755 | 0.72 | DRD2 (0.47) | DRD2DRD3PLAUCD44KDM4E | |
| SCHEMBL7344228 | 0.72 | EPHX2 (0.41) | KDM4ELMNAMAPT | |
| SCHEMBL7352004 | 0.72 | ADRA2C (0.41) | DRD2HTR1AKDM4EALDH1A1LMNA | |
| SCHEMBL2030277 | 0.71 | PLAU (0.45) | DRD2DRD3PLAUMEN1GAA | |
| SCHEMBL3825586 | 0.71 | PLAU (0.45) | DRD2DRD3PLAUMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2241564-B1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | ZERIA PHARM CO LTD (JP) | 2014-04-30 | — | — | EP | claimed |
| US-8501772-B2 | 3,8-diaminotetrahydroquinoline derivative | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-06 | — | — | US | claimed |
| CN-101939313-B | 3,8-diaminotetrahydroquinoline derivative | ZERIA PHARM CO LTD | 2013-05-22 | — | — | CN | claimed |
| US-20130012537-A1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-10 | — | — | US | claimed |
| US-8299255-B2 | 3,8-diaminotetrahydroquinoline derivative | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2012-10-30 | — | — | US | claimed |
| CN-101939313-A | 3,8-diamino tetrahydroquinoline derivative | ZERIA PHARM CO LTD | 2011-01-05 | — | — | CN | claimed |
| US-20100317693-A1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | ZERIA PHARMACEUTICAL CO., LTD (JP) | 2010-12-16 | — | — | US | claimed |
| EP-2241564-A1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | Zeria Pharmaceutical Co., Ltd. (JP) | 2010-10-20 | — | — | EP | claimed |
| EP-2241564-B1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | ZERIA PHARM CO LTD (JP) | 2014-04-30 | — | — | EP | disclosed |
| US-8501772-B2 | 3,8-diaminotetrahydroquinoline derivative | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| US-8501772-B2 | 3,8-diaminotetrahydroquinoline derivative | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| US-8501772-B2 | 3,8-diaminotetrahydroquinoline derivative | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-06 | — | — | US | disclosed |
| CN-101939313-B | 3,8-diaminotetrahydroquinoline derivative | ZERIA PHARM CO LTD | 2013-05-22 | — | — | CN | disclosed |
| CN-101939313-B | 3,8-diaminotetrahydroquinoline derivative | ZERIA PHARM CO LTD | 2013-05-22 | — | — | CN | disclosed |
| WO-2009098901-A1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2009-08-13 | — | — | WO | disclosed |
| US-5436240-A | Schizophrenia, Parkinson's disease, depression or hypotensive agents using tricyclic amines | THE UPJOHN COMPANY (US) | 1995-07-25 | — | — | US | disclosed |
| EP-0480939-B1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | UPJOHN CO (US) | 1995-01-25 | — | — | EP | disclosed |
| US-5273975-A | Heterocyclic amines having central nervous system activity | THE UPJOHN COMPANY (US) | 1993-12-28 | — | — | US | disclosed |
| EP-0480939-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY. | UPJOHN CO (US) | 1992-04-22 | — | — | EP | disclosed |
| WO-1990015058-A1 | HETEROCYCLIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY | THE UPJOHN COMPANY (US) | 1990-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012537-A1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | MC2R, GHRHR, REN | DRD2 533/4885DRD3 293/4885PLAU 4105/4885 |
| US-20100317693-A1 | 3,8-DIAMINOTETRAHYDROQUINOLINE DERIVATIVE | GHSR, GHRHR, GNRHR | DRD2 301/4885DRD3 228/4885PLAU 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.